Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06064071 · ClinicalTrials.gov registry record · NA
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
A NA study of Dry Eye Disease and Meibomian Gland Dysfunction, sponsored by Candela Corporation.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 3
- Study locations
NCT06064071 is a NA study of Dry Eye Disease and Meibomian Gland Dysfunction that is active but no longer recruiting, run by Candela Corporation. The registered enrollment target is 100 participants, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (60% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06064071, a NA study of Dry Eye Disease and Meibomian Gland Dysfunction, is active but no longer recruiting, sponsored by Candela Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
Conditions Studied
Interventions
- DEVICE Nordlys SWT IPL
- PROCEDURE Meibomian Gland Expression (MGX)
- DEVICE Sham Nordlys SWT IPL
Study Locations (3)
Florida
- Center for Excellence in Eye Care - Miami
Massachusetts
- Candela Institute of Excellence - Marlborough
Other
- Av. Del Libertador 662, Piso 17, Dept. 42 - Buenos Aires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2025-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06064071
The ClinicalTrials.gov registry entry for NCT06064071 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (60% lower). The listed sponsor is Candela Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dry Eye Disease appearing as the primary indexed condition, and to 3 interventions - of which Nordlys SWT IPL is the first listed.
NCT06064071 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT06064071 about?
NCT06064071 is a clinical study titled "Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD". Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
What is the current status of trial NCT06064071?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2023-09-18. Estimated completion is 2025-09.
What conditions does trial NCT06064071 study?
This clinical trial studies the following conditions: Dry Eye Disease, Meibomian Gland Dysfunction.
What interventions are being tested in trial NCT06064071?
The interventions under investigation include: Nordlys SWT IPL (DEVICE), Meibomian Gland Expression (MGX) (PROCEDURE), Sham Nordlys SWT IPL (DEVICE).
Who is sponsoring clinical trial NCT06064071?
This trial is sponsored by Candela Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06064071 being conducted?
This trial has 3 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Ocular Comfort With ISTA Tears vs Systane
COMPLETED · NA
-
The Visual Effect of an Investigational Artificial Tear in the Tear Layer.
COMPLETED · NA
-
In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera Slim® for Dry Eye
COMPLETED · NA
-
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
RECRUITING · Phase 3
-
A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
RECRUITING · Phase 4
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.